CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: A cohort study

Arthritis Research and Therapy

Volumn 13, Issue 4, 2011, Pages

  Rodríguez Rodríguez, Luis ^a,b   González Juanatey, Carlos ^c   García Bermúdez, Mercedes ^a   Vázquez Rodríguez, Tomas R ^c   Miranda Filloy, Jose A ^c   Fernández Gutiérrez, Benjamin ^b   Llorca, Javier ^d   Martin, Javier ^a   González Gay, Miguel A ^e  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c HOSPITAL XERAL CALDE   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Atherosclerosis; Cardiovascular disease; CCR5 32; Genetics; Rheumatoid arthritis; Rs333

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL; RHEUMATOID ARTHRITIS;

EID: 80051636504     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3444     Document Type: Article

References (33)

1. Oba Y, Lee JW, Ehrlich LA, Chung HY, Jelinek DF, Callander NS, Horuk R, Choi SJ, Roodman GD. MIP-1α utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 2005, 33:272-278. 10.1016/j.exphem.2004.11.015, 15730850.
2. Schecter AD, Calderon TM, Berman AB, McManus CM, Fallon JT, Rossikhina M, Zhao W, Christ G, Berman JW, Taubman MB. Human vascular smooth muscle cells possess functional CCR5. J Biol Chem 2000, 275:5466-5471. 10.1074/jbc.275.8.5466, 10681524.
3. Lucas AD, Greaves DR. Atherosclerosis: role of chemokines and macrophages. Expert Rev Mol Med 2001, 3:1-18.
4. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal 2004, 16:1201-1210. 10.1016/j.cellsig.2004.04.007, 15337520.
5. Tyner JW, Uchida O, Kajiwara N, Kim EY, Patel AC, O'Sullivan MP, Walter MJ, Schwendener RA, Cook DN, Danoff TM, Holtzman MJ. CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat Med 2005, 11:1180-1187. 10.1038/nm1303, 16208318.
6. Crane IJ, Xu H, Wallace C, Manivannan A, Mack M, Liversidge J, Marquez G, Sharp PF, Forrester JV. Involvement of CCR5 in the passage of Th1-type cells across the blood-retina barrier in experimental autoimmune uveitis. J Leukoc Biol 2006, 79:435-443.
7. Zhao Q. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J Leukoc Biol 2010, 88:41-55. 10.1189/jlb.1009671, 20360402.
8. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapouméroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725. 10.1038/382722a0, 8751444.
9. Pacheco SE, Gibbs RA, Ansari-Lari A, Rogers P. Intranasal immunization with HIV reverse transcriptase: effect of dose in the induction of helper T cell type 1 and 2 immunity. AIDS Res Hum Retroviruses 2000, 16:2009-2017. 10.1089/088922200750054747, 11153084.
10. González P, Alvarez R, Batalla A, Reguero JR, Alvarez V, Astudillo A, Cubero GI, Cortina A, Coto E. Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun 2001, 2:191-195. 10.1038/sj.gene.6363760, 11477473.
11. Szalai C, Duba J, Prohászka Z, Kalina A, Szabó T, Nagy B, Horváth L, Császár A. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD): coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis 2001, 158:233-239. 10.1016/S0021-9150(01)00423-3, 11500196.
12. Petrkova J, Cermakova Z, Lukl J, Petrek M. CC chemokine receptor 5 (CCR5) deletion polymorphism does not protect Czech males against early myocardial infarction. J Intern Med 2005, 257:564-566. 10.1111/j.1365-2796.2005.01491.x, 15910562.
13. Apostolakis S, Baritaki S, Kochiadakis GE, Igoumenidis NE, Panutsopulos D, Spandidos DA. Effects of polymorphisms in chemokine ligands and receptors on susceptibility to coronary artery disease. Thromb Res 2007, 119:63-71. 10.1016/j.thromres.2005.12.016, 16480760.
14. Ghilardi G, Biondi ML, Turri O, Pateri F, D'Eril GM, Scorza R. Genetic control of chemokines in severe human internal carotid artery stenosis. Cytokine 2008, 41:24-28. 10.1016/j.cyto.2007.10.007, 18060801.
15. Gómez-Reino JJ, Pablos JL, Carreira PE, Santiago B, Serrano L, Vicario JL, Balsa A, Figueroa M, de Juan MD. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum 1999, 42:989-992. 10.1002/1529-0131(199905)42:5<989::AID-ANR18>3.0.CO;2-U, 10323455.
16. Kohem CL, Brenol JC, Xavier RM, Bredemeier M, Brenol CV, Dedavid e Silva TL, de Castilhos Mello A, Cañedo AD, Neves AG, Chies JA. The chemokine receptor CCR5 genetic polymorphism and expression in rheumatoid arthritis patients. Scand J Rheumatol 2007, 36:359-364. 10.1080/03009740701393999, 17963165.
17. Prahalad S. Negative association between the chemokine receptor CCR5-Δ32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun 2006, 7:264-268. 10.1038/sj.gene.6364298, 3104293, 16541097.
18. Garred P, Madsen HO, Petersen J, Marquart H, Hansen TM, Freiesleben Sørensen S, Volck B, Svejgaard A, Andersen V. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 1998, 25:1462-1465.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
20. Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Piñeiro A, Garcia-Porrua C, Miranda-Filloy JA, Ollier WE, Martin J, Llorca J. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007, 57:125-132. 10.1002/art.22482, 17266100.
21. Gonzalez-Juanatey C, Llorca J, Martin J, Gonzalez-Gay MA. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 2009, 38:366-371. 10.1016/j.semarthrit.2008.01.012, 18336869.
22. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-Diaz E, Testa A, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007, 57:287-293. 10.1002/art.22530, 17330278.
23. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Martin J, Llorca J. Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum 2008, 38:67-70. 10.1016/j.semarthrit.2008.02.001, 18395772.
24. Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, Martin J, Gonzalez-Gay MA. Effect of anti-tumor necrosis factor α therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006, 55:150-153. 10.1002/art.21707, 16463428.
25. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987, 30:1205-1213. 10.1002/art.1780301102, 2446635.
26. van der Woude D, Lie BA, Lundström E, Balsa A, Feitsma AL, Houwing-Duistermaat JJ, Verduijn W, Nordang GB, Alfredsson L, Klareskog L, Pascual-Salcedo D, Gonzalez-Gay MA, Lopez-Nevot MA, Valero F, Roep BO, Huizinga TW, Kvien TK, Martín J, Padyukov L, de Vries RR, Toes RE. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein. Arthritis Rheum 2010, 62:1236-1245.
27. Afzal AR, Kiechl S, Daryani YP, Weerasinghe A, Zhang Y, Reindl M, Mayr A, Weger S, Xu Q, Willeit J. Common CCR5-del32 frameshift mutation associated with serum levels of inflammatory markers and cardiovascular disease risk in the Bruneck population. Stroke 2008, 39:1972-1978. 10.1161/STROKEAHA.107.504381, 18436884.
28. Yan RT, Anderson TJ, Charbonneau F, Title L, Verma S, Lonn E. Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men. J Am Coll Cardiol 2005, 45:1980-1986. 10.1016/j.jacc.2004.12.079, 15963396.
29. Gonzalez-Juanatey C, Llorca J, Gonzalez-Gay MA. Correlation between endothelial function and carotid atherosclerosis in rheumatoid arthritis patients with long-standing disease. Arthritis Res Ther 2011, 13:R101. 10.1186/ar3382, 21696620.
30. Quinones MP, Martinez HG, Jimenez F, Estrada CA, Dudley M, Willmon O, Kulkarni H, Reddick RL, Fernandes G, Kuziel WA, Ahuja SK, Ahuja SS. CC chemokine receptor 5 influences late-stage atherosclerosis. Atherosclerosis 2007, 195:e92-e103. 10.1016/j.atherosclerosis.2007.03.026, 17466311.
31. Braunersreuther V, Zernecke A, Arnaud C, Liehn EA, Steffens S, Shagdarsuren E, Bidzhekov K, Burger F, Pelli G, Luckow B, Mach F, Weber C. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2007, 27:373-379.
32. van Wanrooij EJ, Happé H, Hauer AD, de Vos P, Imanishi T, Fujiwara H, van Berkel TJ, Kuiper J. HIV entry inhibitor TAK-779 attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2005, 25:2642-2647. 10.1161/01.ATV.0000192018.90021.c0, 16239591.
33. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot AE, Mach F. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004, 94:253-261. 10.1161/01.RES.0000109793.17591.4E, 14656931.